These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 23176613)
1. Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. Roukos D; Batsis C; Baltogiannis G Expert Rev Anticancer Ther; 2012 Oct; 12(10):1245-8. PubMed ID: 23176613 [No Abstract] [Full Text] [Related]
2. Targeted therapy: overcoming drug resistance with clinical cancer genome. Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399 [No Abstract] [Full Text] [Related]
3. Tumor complexity prompts caution about sequencing. Beckman M J Natl Cancer Inst; 2006 Dec; 98(24):1758-9. PubMed ID: 17179472 [No Abstract] [Full Text] [Related]
4. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Roukos DH Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071 [No Abstract] [Full Text] [Related]
5. How next-generation sequencing could change cancer care. O'Hanlon LH J Natl Cancer Inst; 2013 Jun; 105(12):836-8. PubMed ID: 23733908 [No Abstract] [Full Text] [Related]
6. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Gillet JP; Gottesman MM Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109 [No Abstract] [Full Text] [Related]
7. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S; De Jong S; De Vries EG; Mulder NH Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715 [TBL] [Abstract][Full Text] [Related]
8. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy. Farrell NP Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528 [TBL] [Abstract][Full Text] [Related]
9. [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209]. Naito M; Nakanishi O; Tsuruo T Nihon Rinsho; 1997 May; 55(5):1122-7. PubMed ID: 9155163 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of tumor-cell heterogeneity. Schnipper L N Engl J Med; 1986 May; 314(22):1423-31. PubMed ID: 3517651 [No Abstract] [Full Text] [Related]
12. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Shapira A; Livney YD; Broxterman HJ; Assaraf YG Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Wilting RH; Dannenberg JH Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866 [TBL] [Abstract][Full Text] [Related]
14. Cancer and natural selection. Fillon M J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180 [No Abstract] [Full Text] [Related]
15. Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Ohta S Oncogene; 2006 Aug; 25(34):4768-76. PubMed ID: 16892089 [TBL] [Abstract][Full Text] [Related]
16. On or off target: mutations, models, and predictions. Garraway LA; Hahn WC Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617 [TBL] [Abstract][Full Text] [Related]
17. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. Roukos DH Drug Discov Today; 2016 Apr; 21(4):663-73. PubMed ID: 26912452 [TBL] [Abstract][Full Text] [Related]
18. Tumor cell drug resistance and its reversal. Mansouri A; Henle KJ; Nagle WA; Moss AJ SAAS Bull Biochem Biotechnol; 1990 Jan; 3():91-6. PubMed ID: 1366508 [TBL] [Abstract][Full Text] [Related]